231127-paclitaxel-ebewe-ds-v1.0 Page 12 of 18
neuropathy with resultant minor distal weakness and autonomic
neuropathy resulting in paralytic ileus and orthostatic hypotension.
There is a report of a grand mal seizure in a patient receiving paclitaxel and the seizure recurred
after treatment with paclitaxel was recommenced. There is also a second report of a grand
mal seizure in a patient with significant hepatic impairment during infusion with paclitaxel.
Very rare: grand mal seizures, autonomic neuropathy (resulting in paralytic ileus
and orthostatic hypotension), encephalopathy, convulsions, dizziness,
ataxia, headache
Eye disorders
Very rare: Optic nerve and/or visual disturbances (scintillating scotomata),
particularly in patients who have received higher doses than
recommended.
Ear and labyrinth disorders
Very rare: hearing loss, ototoxicity, tinnitus, vertigo
Respiratory, thoracic and mediastinal disorders
Rare: respiratory failure, pulmonary embolism, lung fibrosis, interstitial
pneumonia, dyspnoea, pleural effusion
Very Rare: cough
Skin and appendages
Very common: alopecia
Common: transient and mild nail and skin changes
Rare: pruritus, rash, erythema, radiation recall dermatitis, recall dermatitis.
Local effects: phlebitis following intravenous administration has been
reported. Extravasation leading to oedema, pain, erythema and
induration has been reported. On occasions, extravasation can lead to
cellulitis. Skin discolouration may also occur.
Very Rare: Stevens-Johnson syndrome, epidermal necrolysis, erythema
multiforme, exfoliative dermatitis, urticaria, onycholysis (patients on
therapy should wear sun protection on hands and feet).
Not known: scleroderma
In some cases, the onset of the injection site reaction either occurred during a prolonged
infusion or was delayed by a week to 10 days.
General Disorders and Administration Site Conditions
Very common: mucosal inflammation
Common: injection site reactions (including localised oedema, pain, erythema,
induraton, on occasion extravasation can result in cellulitis, skin fibrosis
and skin necrosis).
Rare: pyrexia, dehydration, asthenia, oedema, malaise
Injection site reactions, including reactions secondary to extravasation, were usually mild and
consisted of erythema, tenderness, skin discolouration, or swelling at the injection site. These
reactions have been observed more frequently with the 24-hour infusion than with the 3-hour
infusion. Recurrence of skin reactions at a site of previous extravasation following
administration of paclitaxel at a different site, i.e. ‘recall’, has been reported rarely.